KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Current Deferred Revenue (2016 - 2025)

Thermo Fisher Scientific's Current Deferred Revenue history spans 17 years, with the latest figure at $2.7 billion for Q4 2025.

  • For the quarter ending Q4 2025, Current Deferred Revenue fell 4.98% year-over-year to $2.7 billion, compared with a TTM value of $2.7 billion through Dec 2025, down 4.98%, and an annual FY2025 reading of $2.7 billion, down 4.98% over the prior year.
  • Current Deferred Revenue for Q4 2025 was $2.7 billion at Thermo Fisher Scientific, down from $2.9 billion in the prior quarter.
  • The five-year high for Current Deferred Revenue was $2.9 billion in Q2 2022, with the low at $1.4 billion in Q2 2021.
  • Average Current Deferred Revenue over 5 years is $2.5 billion, with a median of $2.7 billion recorded in 2021.
  • Year-over-year, Current Deferred Revenue surged 108.89% in 2021 and then decreased 7.28% in 2023.
  • Tracing TMO's Current Deferred Revenue over 5 years: stood at $2.7 billion in 2021, then dropped by 2.03% to $2.6 billion in 2022, then rose by 3.38% to $2.7 billion in 2023, then rose by 6.06% to $2.9 billion in 2024, then dropped by 4.98% to $2.7 billion in 2025.
  • Per Business Quant, the three most recent readings for TMO's Current Deferred Revenue are $2.7 billion (Q4 2025), $2.9 billion (Q3 2025), and $2.8 billion (Q2 2025).